Stem cell patent indicates support for regenerative medicine research

The US Patent and Trademark Office has issued a patent to Israeli biotechnology company BrainStorm Cell Therapeutics, which covers stem cell technology that can be used in the treatment of neurodegenerative diseases such as Parkinson’s and Alzheimer’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Chinese biotech strikes billion dollar deal in nextgen cancer race

20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.

Asia

Novo Nordisk secures China win ahead of key patent expiration

6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.

Asia

Novo Nordisk ramps up semaglutide defence as generics lurk

9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

More features

Moderna VP and regulatory expert moves to private practice

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Pearce IP grows practice with senior patent hire

Sanofi suffers setback in insulin monopoly dispute

Firm adds seven-lawyer team in second major merger

Eli Lilly’s Mounjaro tops list of cyber squatter targets

The quantum advantage: IP considerations for the next generation of life sciences innovation

Fed Circ overturns PTAB decision in $83.4m DNA case

Stem cell patent indicates support for regenerative medicine research

More on this story

Editor's picks

Editor's picks

More features